Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12‐Month Real‐World Results

ABSTRACT Aims This study assessed the real‐world effectiveness of tirzepatide in commercially insured individuals without diabetes, eligible for obesity medications (OMs), including glucagon like‐peptide‐1 receptor agonist (GLP‐1 RA)‐naïve individuals (i.e., no GLP‐1 RA prescription during the 12‐month pre‐index period) and GLP‐1 RA‐experienced individuals. Methods This retrospective, observational cohort study used Optum's de‐identified Market Clarity Data (Optum Market Clarity). Adults with ≥ 1 prescription claim for tirzepatide between November 2023 and March 2024, with continuous medical/pharmacy enrollment for ≥ 12 months pre‐index and post‐index and available pre‐ and post‐index data were included. Baseline demographics, clinical characteristics, and treatment effectiveness (change from baseline in weight, body mass index, and cardiometabolic risk factors) were assessed among OM‐eligible individuals who were persistent on tirzepatide for ≥ 12 months. Results The GLP‐1 RA‐naïve and experienced cohorts included 230 individuals (mean age: 49.5 years, 72.2% female) and 123 individuals (mean age: 48.9 years, 81.3% female), respectively, who were persistent on tirzepatide for 12 months with documented pre‐ and post‐index weight measurements. At baseline, more than 85% of individuals in each cohort had ≥ 1 obesity‐related complication, most commonly dyslipidemia, hypertension, and prediabetes. At 12 months post‐index, the GLP‐1 RA‐naïve cohort achieved a mean weight reduction of 19.3%, while the GLP‐1 RA‐experienced cohort achieved a mean weight reduction of 13.1%. Conclusions After 12 months of persistent tirzepatide use, individuals experienced clinically meaningful weight reduction, comparable to outcomes reported in clinical trials. These real‐world findings were observed both in GLP‐1 RA‐naïve and experienced individuals.